Integrin Inhibitors for Ulcerative Colitis Treatment
This article describes the mechanism of integrin inhibitors' action, the usefulness, and positioning of vedolizumab and carotegrast methyl, which are currently available for clinical use to treat ulcerative colitis, and the status of integrin inhibitor development.
Authors
- Akira Yamamiya (ORCID: https://orcid.org/0000-0002-5158-5606)
- Keiichi Tominaga (ORCID: https://orcid.org/0000-0002-3716-3386)
- Shunsuke Kojimahara
- Mimari Kanazawa (ORCID: https://orcid.org/0000-0003-2243-4267)
- Takeshi Sugaya (ORCID: https://orcid.org/0000-0001-9139-3062)
- Takanao Tanaka (ORCID: https://orcid.org/0000-0002-3714-1208)
- Atsushi Irisawa (ORCID: https://orcid.org/0000-0002-2271-2717)
Institutions
- Dokkyo University (JP)
- Dokkyo Medical University (JP)
Publication Details
- Journal
- Digestion
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1159/000550032
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00